BioSpace News Archive

bioAffinity Technologies, Inc . (NASDAQ: BIAF; BIAFW) today announced publication of “ Detection of early-stage lung cancer in sputum using automated flow cytometry and machine learning ” detailing results of the Company’s clinical trial for its non-invasive diagnostic CyPath ® Lung in Respiratory Research, one of the leading peer-reviewed open access journals in the field of respiratory medicine.

MediXall Group Inc. is pleased to announce that MediXall and Health Karma Chief Executive Officer, Travis Jackson has been invited to present at the Healthcare IT Virtual Conference, presented by Maxim Group LLC and hosted by M-Vest, on Wednesday, January 25th, 2023 at 2:45 pm ET.

Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today provided an update on the clinical trials with Bentrio® in seasonal allergic rhinitis (SAR) and acute COVID-19.

Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) , today announced the appointment of Michael Nketiah as Senior Vice President of Quality, Clinical and Regulatory.

eGenesis, a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, today announced that Knut Niss, Ph.D., has joined the company as Chief Technology Officer.

Vistagen today announced the first cohort of healthy volunteers has been dosed in its U.S. Phase 1 clinical trial of PH10, the Company’s investigational pherine nasal spray in development for the treatment of major depressive disorder (MDD).

Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN) today announces the initiation of Good Laboratory Practice (GLP) toxicology studies of its lead oncology program, QN-302, a G4-selective transcription inhibitor currently in development for the treatment of G4 (G-Quadruplex) expressing solid tumors, including pancreatic cancer.

TetraScience, the Scientific Data Cloud company, proudly announces its ISO/IEC 27001 certification, which builds upon an ongoing corporate commitment to compliance and process formalization for biopharma customers.

Precision for Medicine, the first global, precision medicine clinical research services organization, today announced the strategic acquisition of SolveBio by QuartzBio.

Aetion, the global leader in real-world evidence (RWE) technology and analytics, today announced a five-year research collaboration with the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) to advance research using novel oncology real-world data (RWD) sources through platform analytics on the Aetion Evidence Platform® (AEP).